

# Angela Lamarca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2249067/publications.pdf>

Version: 2024-02-01

116  
papers

4,855  
citations

172457

29  
h-index

106344

65  
g-index

118  
all docs

118  
docs citations

118  
times ranked

4490  
citing authors

#	ARTICLE	IF	CITATIONS
1	Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy. <i>British Journal of Cancer</i> , 2022, 126, 693-705.	6.4	18
2	Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 1999-2019.	7.0	20
3	Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <i>ESMO Open</i> , 2022, 7, 100377.	4.5	8
4	How I treat biliary tract cancer. <i>ESMO Open</i> , 2022, 7, 100378.	4.5	45
5	Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes. <i>Oncologist</i> , 2022, 27, 97-103.	3.7	6
6	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. <i>Journal of Hepatology</i> , 2022, 76, 1109-1121.	3.7	119
7	Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice. <i>Cancers</i> , 2022, 14, 1017.	3.7	2
8	Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1198-1208.	1.0	3
9	Targeted Therapies for Perihilar Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 1789.	3.7	7
10	Work-Up and Outcome of Hepatic Resection for Peri-Hilar Cholangiocarcinoma (PH-CCA) without Staging Laparoscopy. <i>Cancers</i> , 2022, 14, 1841.	3.7	0
11	Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy. <i>Acta Oncológica</i> , 2022, 61, 583-590.	1.8	4
12	Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry. <i>Cancers</i> , 2022, 14, 2389.	3.7	10
13	Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. <i>Gut</i> , 2022, , gutjnl-2022-327099.	12.1	11
14	Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1009-1015.	2.4	2
15	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. <i>Hepatology</i> , 2021, 73, 2311-2325.	7.3	40
16	Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability. <i>Neuroendocrinology</i> , 2021, 111, 831-839.	2.5	7
17	Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review. <i>Neuroendocrinology</i> , 2021, 111, 354-369.	2.5	17
18	Outcomes in older patients with biliary tract cancer. <i>European Journal of Surgical Oncology</i> , 2021, 47, 569-575.	1.0	5

#	ARTICLE	IF	CITATIONS
19	Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 377-388.	4.1	5
20	Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3 <sup>rd</sup> -line treatment. <i>World Journal of Gastroenterology</i> , 2021, 27, 976-989.	3.3	3
21	HPB cancers in older patients   inclusion of older/senior patients in clinical trials. <i>European Journal of Surgical Oncology</i> , 2021, 47, 597-602.	1.0	4
22	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 94, 102168.	7.7	6
23	Ivosidenib: an investigational drug for the treatment of biliary tract cancers. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 301-307.	4.1	5
24	Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. <i>ESMO Open</i> , 2021, 6, 100104.	4.5	15
25	Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2021, 22, 690-701.	10.7	396
26	Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. <i>Current Treatment Options in Oncology</i> , 2021, 22, 73.	3.0	6
27	Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103328.	4.4	25
28	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). <i>Journal of Clinical Oncology</i> , 2021, 39, 2304-2312.	1.6	49
29	Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e288-e289.	10.7	2
30	The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 3779.	3.7	16
31	Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 975-983.	4.1	7
32	REPLY:. <i>Hepatology</i> , 2021, 74, 1129-1131.	7.3	2
33	Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?. <i>Cancers</i> , 2021, 13, 4152.	3.7	4
34	Systemic therapies in elderly patients with advanced hepatocellular carcinoma: do not forget metronomic capecitabine. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2209-2210.	1.0	0
35	Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. <i>Endocrine-Related Cancer</i> , 2021, 28, 549-561.	3.1	10
36	REPLY:. <i>Hepatology</i> , 2021, 74, 2319-2321.	7.3	1

#	ARTICLE	IF	CITATIONS
37	Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2248-2255.	1.0	8
38	Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102258.	7.7	45
39	Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1073-1085.	2.0	4
40	Gender representation in authorship in later-phase systemic clinical trials in biliary tract cancer (BTC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 348-348.	1.6	0
41	Molecular profiling of advanced pancreatic ductal adenocarcinoma (PDAC): Role of ctDNA.. <i>Journal of Clinical Oncology</i> , 2021, 39, 425-425.	1.6	0
42	The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2021, 10, 403.	2.4	4
43	Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 101, 102299.	7.7	3
44	Pancreatic Enzyme Replacement Therapy for Patients Diagnosed With Pancreaticobiliary Cancer. <i>Pancreas</i> , 2021, 50, 1254-1259.	1.1	4
45	Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2020, 112, 200-210.	6.3	90
46	Temozolomide-Capécitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration. <i>Neuroendocrinology</i> , 2020, 110, 155-157.	2.5	8
47	Identification of Areas for Improvement in the Management of Bone Metastases in Patients with Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2020, 110, 688-696.	2.5	6
48	High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2020, 110, 891-898.	2.5	34
49	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. <i>Cancer Treatment Reviews</i> , 2020, 84, 101936.	7.7	73
50	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. <i>British Journal of Cancer</i> , 2020, 123, 1047-1059.	6.4	37
51	Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). <i>Cancers</i> , 2020, 12, 1988.	3.7	12
52	Fibrolamellar carcinoma: Challenging the challenge. <i>European Journal of Cancer</i> , 2020, 137, 144-147.	2.8	5
53	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. <i>Cancer Treatment Reviews</i> , 2020, 89, 102084.	7.7	61
54	Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 1682-1688.	1.1	13

#	ARTICLE	IF	CITATIONS
55	Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers. <i>Journal of Clinical Medicine</i> , 2020, 9, 2854.	2.4	61
56	Current and New Biomarkers for Early Detection, Prognostic Stratification, and Management of Gallbladder Cancer Patients. <i>Cancers</i> , 2020, 12, 3670.	3.7	12
57	FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?. <i>ESMO Open</i> , 2020, 5, e000633.	4.5	1
58	The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-standard. <i>Pancreatology</i> , 2020, 20, 668-675.	1.1	12
59	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). <i>BMI Open</i> , 2020, 10, e034527.	1.9	11
60	Safety, tolerability and clinical implementation of $^{68}\text{Ga}$ -ready-to-use $^{68}\text{Ga}$ 68gallium-DOTA0-Tyr3-octreotide ( $^{68}\text{Ga}$ -DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). <i>ESMO Open</i> , 2020, 5, e000650.	4.5	12
61	Reaching out beyond first-line treatments in advanced biliary tract cancers. <i>Annals of Oncology</i> , 2020, 31, 1099-1102.	1.2	1
62	Molecular targeted therapies: Ready for $\text{prime time}$ in biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 170-185.	3.7	226
63	Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trial. <i>Future Oncology</i> , 2020, 16, 2375-2384.	2.4	62
64	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	17.8	1,155
65	PD-1 Systematic review and meta-analysis of the efficacy of chemotherapeutic regimens in advanced gallbladder cancer: Assessing current practice and treatment benefit. <i>Annals of Oncology</i> , 2020, 31, S212.	1.2	1
66	Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1035-1043.e2.	0.5	49
67	Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2358-2371.	6.4	9
68	Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis. <i>Journal of Clinical Medicine</i> , 2020, 9, 273.	2.4	89
69	The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA).. <i>Journal of Clinical Oncology</i> , 2020, 38, e16686-e16686.	1.6	7
70	Clinical and Translational Research Challenges in Biliary Tract Cancers. <i>Current Medicinal Chemistry</i> , 2020, 27, 4756-4777.	2.4	21
71	Clinical and Translational Research Challenges in Neuroendocrine Tumours. <i>Current Medicinal Chemistry</i> , 2020, 27, 4823-4839.	2.4	5
72	Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours. <i>World Journal of Clinical Oncology</i> , 2020, 11, 205-216.	2.3	4

#	ARTICLE	IF	CITATIONS
73	RELEVANT study: Patient (Pt) and physician (PI) perspectives on meaningful outcomes in advanced pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2020, 38, 150-150.	1.6	0
74	Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. Journal of Clinical Oncology, 2019, 37, 2571-2580.	1.6	49
75	Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study. Clinical Cancer Research, 2019, 25, 6692-6699.	7.0	18
76	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. Scientific Reports, 2019, 9, 11610.	3.3	36
77	Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the study of cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging. Annals of Oncology, 2019, 30, v280-v281.	1.2	1
78	Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: A systematic review and meta-analysis. Annals of Oncology, 2019, 30, v25.	1.2	4
79	<p>Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes</p>. Cancer Management and Research, 2019, Volume 11, 7537-7556.	1.9	3
80	Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice. Journal of Clinical Medicine, 2019, 8, 1630.	2.4	10
81	Unusual skull base metastasis from neuroendocrine tumor: a case report. Journal of Medical Case Reports, 2019, 13, 273.	0.8	0
82	Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver International, 2019, 39, 98-107.	3.9	171
83	18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. Journal of Hepatology, 2019, 71, 115-129.	3.7	76
84	In the literature: June 2019. ESMO Open, 2019, 4, e000547.	4.5	3
85	Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients'™ Outcome in Neuroendocrine Tumors (NET)â€™The GREPONET Study. Oncologist, 2019, 24, e1082-e1090.	3.7	26
86	Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC). Clinical and Translational Oncology, 2019, 21, 950-953.	2.4	9
87	ABC-06   A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.. Journal of Clinical Oncology, 2019, 37, 4003-4003.	1.6	166
88	Systemic therapy of gallbladder cancer: review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer. Chinese Clinical Oncology, 2019, 8, 43-43.	1.2	16
89	Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World Journal of Gastrointestinal Oncology, 2019, 11, 102-116.	2.0	2
90	68Gallium DOTANOC-PET Imaging in Lung Carcinoids: Impact on Patients' Management. Neuroendocrinology, 2018, 106, 128-138.	2.5	15

#	ARTICLE	IF	CITATIONS
91	Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. <i>British Journal of Cancer</i> , 2018, 118, 181-188.	6.4	23
92	The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. <i>PLoS ONE</i> , 2018, 13, e0206007.	2.5	14
93	Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. <i>Cancer Treatment Reviews</i> , 2018, 70, 168-177.	7.7	55
94	Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 723-731.	3.0	37
95	HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 141-157.	5.9	119
96	Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw277.	6.3	28
97	New Horizons for Precision Medicine in Biliary Tract Cancers. <i>Cancer Discovery</i> , 2017, 7, 943-962.	9.4	419
98	Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma. <i>Current Oncology Reports</i> , 2017, 19, 50.	4.0	17
99	Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours. <i>Clinical and Translational Oncology</i> , 2017, 19, 579-586.	2.4	32
100	Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 909.	4.1	21
101	Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery. <i>Surgical Oncology</i> , 2016, 25, 223-228.	1.6	13
102	Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3616-3627.	3.6	10
103	Telotristat ethyl: a new option for the management of carcinoid syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2487-2498.	1.8	27
104	Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?. <i>Cancer Treatment Reviews</i> , 2016, 44, 26-41.	7.7	45
105	<sup>18</sup> F-FLT PET imaging of cellular proliferation in pancreatic cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 158-169.	4.4	10
106	Prevalence of symptomatic pancreatic exocrine insufficiency in patients with pancreatic malignancy: nutritional intervention may improve survival. <i>Cancer Research Frontiers</i> , 2016, 2, 352-367.	0.2	10
107	Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. <i>World Journal of Gastroenterology</i> , 2016, 22, 6065.	3.3	23
108	Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. <i>European Journal of Cancer</i> , 2015, 51, 1694-1703.	2.8	25

#	ARTICLE	IF	CITATIONS
109	Abc-06: a Randomised Phase Iii, Multi-Centre, Open-Label Study of Active Symptom Control (Asc) Alone or Asc with Oxaliplatin / 5-Fu Chemotherapy for Patients with Locally Advanced / Metastatic Biliary Tract Cancers (Abc) Previously Treated with Cisplatin / Gemcitabine Chemotherapy.. Annals of Oncology, 2014, 25, iv252.	1.2	9
110	Second-line chemotherapy in advanced biliary cancer: a systematic review. Annals of Oncology, 2014, 25, 2328-2338.	1.2	279
111	Reply to the letter to the editor "Second-line chemotherapy in advanced biliary cancer: the present now will later be past" by Vivaldi et al.. Annals of Oncology, 2014, 25, 2444-2445.	1.2	1
112	Looking Beyond Chemotherapy in Patients with Advanced, Well-differentiated, Pancreatic Neuroendocrine Tumors. The Journal of Oncopathology, 2014, 2, 15-25.	0.1	2
113	Should Patients with Resected Bile Duct Cancer Receive an Adjuvant Treatment?. The Journal of Oncopathology, 2014, 2, 57-68.	0.1	3
114	Pilot, proof-of-concept studies for determining the feasibility of the use of FLT-PET in patients with pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, TPS4146-TPS4146.	1.6	2
115	Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence. Endocrine Abstracts, 0, , .	0.0	1
116	Latest advances in cholangiocarcinoma. Liver Cancer International, 0, , .	1.3	0